Led by RA Capital Management, the investment will fuel the advancement of the company's biomanufacturing platforms, NTxscribe® and NTxpress®. Acceleration of these technology foundations will enable distribution of manufacturing capabilities globally, ultimately providing solutions to prepare for future pandemic events, personalized medicine therapy, and increased access to critical vaccines and medicines.

Nature's Toolbox is advancing the healthcare industry with their next generation biomanufacturing solutions. NTx, based in Rio Rancho, New Mexico, is developing innovative systems like NTxpress® and NTxscribe® to enable manufacturing of mRNA vaccines and protein therapeutics in an eco-friendly and sustainable way. These easily scalable processes enable NTx's platform to scale from personalized medicine dosage to pandemic volume.